Erratum: CK2 mediates phosphorylation and ubiquitin-mediated degradation of the PML tumor suppressor (Molecular Cellular Biochemistry (2008) vol. 316 (149-154) 10.1007/s11010-008-9812-7);CK2 mediates phosphorylation and ubiquitin-mediated degradation of the PML tumor suppressor

Molecular and Cellular Biochemistry

Volumn 316, Issue 1-2, 2008, Pages 149-154

  Scaglioni, Pier P ^a   Yung, T M ^b   Choi, S C ^a   Baldini, C ^a   Konstantinidou, G ^a   Pandolfi, P P ^c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

CK2; Lung cancer pathogenesis; PML; Protein polyubiquitination

Indexed keywords

CASEIN KINASE II; EMODIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PROMYELOCYTIC LEUKEMIA TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL STRESS; ENZYME ACTIVITY; GROWTH INHIBITION; HUMAN; LUNG NON SMALL CELL CANCER; NONHUMAN; OSMOTIC STRESS; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; SENESCENCE; TUMOR; TUMOR XENOGRAFT; UBIQUITINATION;

EID: 50649105487     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-009-0122-5     Document Type: Erratum

References (41)

1. Scaglioni PP, Yung TM, Cai LF, Erdjument-Bromage H, Kaufman AJ, Singh B et al (2006) A CK2-dependent mechanism for degradation of the PML tumor suppressor. Cell 126:269-283. doi: 10.1016/j.cell.2006.05.041
2. Bernardi R, Pandolfi PP (2007) Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol 8:1006-1016. doi: 10.1038/nrm2277
3. Matsushita H, Scaglioni PP, Bhaumik M, Rego EM, Cai LF, Majid SM et al (2006) In vivo analysis of the role of aberrant histone deacetylase recruitment and RAR alpha blockade in the pathogenesis of acute promyelocytic leukemia. J Exp Med 203:821-828. doi: 10.1084/jem.20050616
4. Scaglioni PP, Pandolfi PP (2007) The theory of APL revisited. Curr Top Microbiol Immunol 313:85-100
5. Wang ZG, Ruggero D, Ronchetti S, Zhong S, Gaboli M, Rivi R et al (1998) PML is essential for multiple apoptotic pathways. Nat Genet 20:266-272. doi: 10.1038/3030
6. Ferbeyre G, de Stanchina E, Querido E, Baptiste N, Prives C, Lowe SW (2000) PML is induced by oncogenic ras and promotes premature senescence. Genes Dev 14:2015-2027
7. Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S et al (2000) PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 406:207-210. doi: 10.1038/35021000
8. Salomoni P, Bernardi R, Bergmann S, Changou A, Tuttle S, Pandolfi PP (2005) The promyelocytic leukemia protein PML regulates c-Jun function in response to DNA damage. Blood 105:3686-3690. doi: 10.1182/ blood-2004-09-3782
9. Trotman LC, Alimonti A, Scaglioni PP, Koutcher JA, Cordon-Cardo C, Pandolfi PP (2006) Identification of a tumor suppressor network opposing nuclear Akt function. Nature 441:523-527. doi: 10.1038/nature04809
10. Fogal V, Gostissa M, Sandy P, Zacchi P, Sternsdorf T, Jensen K et al (2000) Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J 19:6185-6195. doi: 10.1093/emboj/19.22.6185
11. Bernardi R, Guernah I, Jin D, Grisendi S, Alimonti A, Teruya-Feldstein J et al (2006) PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature 442:779-785. doi: 10.1038/nature05029
12. Lin HK, Bergmann S, Pandolfi PP (2004) Cytoplasmic PML function in TGF-beta signalling. Nature 431:205-211. doi: 10.1038/nature02783
13. Pinna LA (2002) Protein kinase CK2: A challenge to canons. J Cell Sci 115:3873-3878. doi: 10.1242/jcs.00074
14. Ahmed K, Gerber DA, Cochet C (2002) Joining the cell survival squad: An emerging role for protein kinase CK2. Trends Cell Biol 12:226-230. doi: 10.1016/S0962-8924(02)02279-1
15. Buchou T, Vernet M, Blond O, Jensen HH, Pointu H, Olsen BB et al (2003) Disruption of the regulatory beta subunit of protein kinase CK2 in mice leads to a cell-autonomous defect and early embryonic lethality. Mol Cell Biol 23:908-915. doi: 10.1128/MCB.23.3.908-915.2003
16. Padmanabha R, Chen-Wu JL, Hanna DE, Glover CV (1990) Isolation, sequencing, and disruption of the yeast CKA2 gene: Casein kinase II is essential for viability in Saccharomyces cerevisiae. Mol Cell Biol 10:4089-4099
17. Fraser AG, Kamath RS, Zipperlen P, Martinez-Campos M, Sohrmann M, Ahringer J (2000) Functional genomic analysis of C elegans chromosome I by systematic RNA interference. Nature 408:325-330. doi: 10.1038/35042517
18. O-charoenrat P, Rusch V, Talbot SG, Sarkaria I, Viale A, Socci N, Ngai I, Rao P, Singh B (2004) Casein kinase II alpha subunit and C1-inhibitor are independent predictors of outcome in patients with squamous cell carcinoma of the lung. Clin Cancer Res 10:5792-5803. doi: 10.1158/ 1078-0432.CCR-03-0317
19. Landesman-Bollag E, Romieu-Mourez R, Song DH, Sonenshein GE, Cardiff RD, Seldin DC (2001) Protein kinase CK2 in mammary gland tumorigenesis. Oncogene 20:3247-3257. doi: 10.1038/sj.onc.1204411
20. Seldin DC, Leder P (1995) Casein kinase II alpha transgene-induced murine lymphoma: Relation to theileriosis in cattle. Science 267:894-897. doi: 10.1126/science.7846532
21. Kato T Jr, Delhase M, Hoffmann A, Karin M (2003) CK2 Is a C-terminal IkappaB kinase responsible for NF-kappaB activation during the UV response. Mol Cell 12:829-839. doi: 10.1016/S1097-2765(03)00358-7
22. Di Maira G, Salvi M, Arrigoni G, Marin O, Sarno S, Brustolon F et al (2005) Protein kinase CK2 phosphorylates and upregulates Akt/PKB. Cell Death Differ 12:668-677. doi: 10.1038/sj.cdd.4401604
23. Song DH, Sussman DJ, Seldin DC (2000) Endogenous protein kinase CK2 participates in Wnt signaling in mammary epithelial cells. J Biol Chem 275:23790-23797. doi: 10.1074/jbc.M909107199
24. Desagher S, Osen-Sand A, Montessuit S, Magnenat E, Vilbois F, Hochmann A et al (2001) Phosphorylation of bid by casein kinases I and II regulates its cleavage by caspase 8. Mol Cell 8:601-611. doi: 10.1016/ S1097-2765(01)00335-5
25. Gurrieri C, Capodieci P, Bernardi R, Scaglioni PP, Nafa K, Rush LJ et al (2004) Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst 96:269-279
26. Koken MH, Linares-Cruz G, Quignon F, Viron A, Chelbi-Alix MK, Sobczak-Thepot J, Juhlin L, Degos L, Calvo F, de The H (1995) The PML growth-suppressor has an altered expression in human oncogenesis. Oncogene 10:1315-1324
27. Zhang P, Chin W, Chow LT, Chan AS, Yim AP, Leung SF et al (2000) Lack of expression for the suppressor PML in human small cell lung carcinoma. Int J Cancer 85:599-605. doi: 10.1002/ (SICI)1097-0215(20000301)85:5<599::AID-IJC1>3.0.CO;2-#
28. Meggio F, Marchiori F, Borin G, Chessa G, Pinna LA (1984) Synthetic peptides including acidic clusters as substrates and inhibitors of rat liver casein kinase TS (type-2). J Biol Chem 259:14576-14579
29. Meggio F, Pinna LA (2003) One-thousand-and-one substrates of protein kinase CK2? FASEB J 17:349-368. doi: 10.1096/fj.02-0473rev
30. Sayed M, Kim SO, Salh BS, Issinger OG, Pelech SL (2000) Stress-induced activation of protein kinase CK2 by direct interaction with p38 mitogen-activated protein kinase. J Biol Chem 275:16569-16573. doi: 10.1074/jbc.M000312200
31. Yamada M, Katsuma S, Adachi T, Hirasawa A, Shiojima S, Kadowaki T et al (2005) Inhibition of protein kinase CK2 prevents the progression of glomerulonephritis. Proc Natl Acad Sci USA 102:7736-7741. doi: 10.1073/ pnas.0409818102
32. Keller DM, Zeng X, Wang Y, Zhang QH, Kapoor M, Shu H et al (2001) A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1. Mol Cell 7:283-292. doi: 10.1016/S1097-2765(01)00176-9
33. Hupp TR, Meek DW, Midgley CA, Lane DP (1992) Regulation of the specific DNA binding function of p53. Cell 71:875-886. doi: 10.1016/ 0092-8674(92)90562-Q
34. Bruins W, Zwart E, Attardi LD, Iwakuma T, Hoogervorst EM, Beems RB et al (2004) Increased sensitivity to UV radiation in mice with a p53 point mutation at Ser389. Mol Cell Biol 24:8884-8894. doi: 10.1128/ MCB.24.20.8884-8894.2004
35. Schuster N, Gotz C, Faust M, Schneider E, Prowald A, Jungbluth A et al (2001) Wild-type p53 inhibits protein kinase CK2 activity. J Cell Biochem 81:172-183. doi: 10.1002/ 1097-4644(20010401)81:1<172::AID-JCB1033>3.0.CO;2-O
36. Roux PP, Blenis J (2004) ERK and p38 MAPK-activated protein kinases: A family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 68:320-344. doi: 10.1128/MMBR.68.2.320-344.2004
37. Esteva FJ, Sahin AA, Smith TL, Yang Y, Pusztai L, Nahta R et al (2004) Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer 100:499-506. doi: 10.1002/cncr.11940
38. Elenitoba-Johnson KS, Jenson SD, Abbott RT, Palais RA, Bohling SD, Lin Z et al (2003) Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy. Proc Natl Acad Sci USA 100:7259-7264. doi: 10.1073/ pnas.1137463100
39. Hildesheim J, Awwad RT, Fornace AJ Jr (2004) p38 Mitogen-activated protein kinase inhibitor protects the epidermis against the acute damaging effects of ultraviolet irradiation by blocking apoptosis and inflammatory responses. J Invest Dermatol 122:497-502. doi: 10.1111/ j.1523-1747.2004.22229.x
40. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617. doi: 10.1056/NEJMoa030288
41. Mitchell BS (2003) The proteasome - an emerging therapeutic target in cancer. N Engl J Med 348:2597-2598. doi: 10.1056/NEJMp030092